

Executive Summary
Collaborative Working Project Immunology

Organisations involved

Barts NHS Trust / AbbVie

Summary

This collaboration aims to improve health and quality of life of people with Immune Mediated Inflammatory Diseases (IMID) through developing a patient-centered care model for IMID; centralising care in a Centre of Excellence (CoE). This requires a patient-oriented functional structure that integrates health professionals around IMID diseases in a coordinated manner, with the common goal of making effective use of available resources and improving patient experience and health outcomes.

The project will start in July 2024 and run for 2 years.

Background

Limited NHS resources demand reform of services which deliver high quality of care and can be shown to be cost efficient. Patients suffering from multiple IMIDs are heavily dependent on a traditional model of care, which is fragmented and based on individual specialties, not offering streamlined and joined up care, with a high budgetary impact.

Project Objectives

- Raise the Standards of Care for patients with complex multiple IMIDs
- Improve health outcomes and experience of patients with IMID
- Ensure all HCPs involved in the patient journey are supported to expand the skills and enable the optimum use of advanced practitioners
- Develop an integrated patient pathway
- Demonstrate success and the viability of CoE

Benefits

Benefits to patient

- Improve quality and consistency of care for patients with complex multiple IMID
- Enhanced patient satisfaction and empowering patients to access specialist services when needed
- A reduction in routine outpatient appointments saving patients time and costs associated with coming into hospital
- Reduction of hospital admissions and A&E visits
- Minimise disruptions to people's lives as centralised care

Benefits to the NHS

- First CoE for IMID in UK
- Optimisation of service delivery by centralising care, patient data and appointments enhancing / streamlining specialist service provision

- Co-ordination of patient care and multidisciplinary teamwork / cross functional working between specialties
- Greater understanding of costs associated with current IMID services

Benefits to AbbVie

- Demonstrated partner of choice for opportunities to improve patient standards of care
- Support AbbVie's position as leaders within the immunology landscape creating first CoE for IMID patients
- Gain better understanding of the NHS challenges to provide specialist patient care to inform further initiatives to improve standards of care
- The outcomes of the Collaborative Working (CW) will be fed back into the ongoing work of the national report as a demonstration of proof of concept

Funding and Resources

This project is a shared contribution of time between Barts NHS Trust and AbbVie. Funding for meeting space, resulting meeting materials and £49,999 for 1 year of an IMID Coordinator will be provided by AbbVie.

Date of Preparation: June 2024 UK-ABBV-230449

Contact

AbbVie Ltd

AbbVie House

Vanwall Business Park

Vanwall Road

Maidenhead

Berkshire

SL6 4UB

centralisationteam@abbvie.com

This executive summary is published on: www.abbvie.co.uk